Pharmaceuticals

Growth In The Gabapentin Market Is Being Driven By Increasing Human Immunodeficiency Virus (HIV) Or Acquired Immune Deficiency Syndrome (AIDS) Prevalence Drives Growth Of The

April 30, 2026April 30, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Gabapentin Market Expected To Change From 2026 To 2030?

The gabapentin market has experienced strong expansion in recent years. Its value is anticipated to rise from $3.01 billion in 2025 to $3.26 billion in 2026, at a compound annual growth rate (CAGR) of 8.4%. The growth observed in previous periods is linked to the increased adoption of epilepsy treatments, the widespread occurrence of neuropathic pain, the accessibility of generic drugs, established physician prescribing habits, and the overall burden of chronic diseases.

The gabapentin market size is anticipated to undergo significant expansion over the coming years. It is forecast to reach $4.45 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 8.1%. The expansion during this forecast period can be attributed to factors such as an aging population, the increase in diabetic neuropathy, greater generic penetration, the growth of outpatient pain management solutions, and the rise of telemedicine prescriptions. Prominent trends expected in the forecast period include a growing utilization in neuropathic pain management, an increased preference for generic formulations, the broadening of chronic pain treatment programs, the evolution of oral solid dosage forms, and a rise in prescriptions for neurological disorders.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24544&type=smp

Which Drivers Are Supporting The Gabapentin Market Growth?

The gabapentin market is anticipated to grow, propelled by the rising prevalence of epilepsy. Epilepsy is defined as a neurological disorder marked by recurring seizures that originate from abnormal electrical brain activity. The increase in epilepsy cases is largely attributed to the expanding elderly population, given that aging elevates the risk of neurological conditions capable of inducing seizures. Gabapentin addresses epilepsy by moderating atypical nerve activity within the brain and reducing signals that provoke seizures; its mechanism involves targeting calcium channels to aid in preventing seizure onset. For example, as reported in February 2024 by the World Health Organization (WHO), a Switzerland-based intergovernmental organization, approximately 50 million individuals worldwide are affected by epilepsy. A significant nearly 80% of these individuals reside in low- and middle-income countries, and up to 70% have the potential to live without seizures if they receive proper diagnosis and treatment. Annually, an estimated 5 million individuals globally receive a new epilepsy diagnosis; high-income countries report this rate to be about 49 per 100,000, whereas in low- and middle-income countries, it can reach up to 139 per 100,000. This escalating prevalence of epilepsy is consequently propelling the expansion of the gabapentin market.

How Is Segmentation Applied In The Gabapentin Market Segment Analysis?

The gabapentin market covered in this report is segmented –

1) By Type: Generic, Branded

2) By Dosage Form: Tablet, Capsule, Oral Solution

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

4) By Application: Epilepsy, Neuropathic Pain, Restless Legs Syndrome, Other Applications

Subsegments:

1) By Generic: Gabapentin Immediate Release (IR), Gabapentin Extended Release (ER), Gabapentin Capsules, Gabapentin Tablets, Gabapentin Oral Solution

2) By Branded: Neurontin, Gralise, Horizant, Other Branded Formulations

Which Trends Are Guiding The Direction Of The Gabapentin Market?

Key companies operating in the gabapentin market are prioritizing the development of advanced formulations, such as bioequivalent tablets, to boost therapeutic effectiveness and broaden available treatment options for neurological conditions. Bioequivalent tablets are generic medications designed to deliver an identical quantity of the active component into the bloodstream with the same speed and efficiency as the original branded product, thus guaranteeing comparable safety and therapeutic results. For instance, in March 2024, Strides Pharma Science Limited, an India-based pharmaceutical company, launched Gabapentin Tablets USP in 600 mg and 800 mg strengths, which secured approval from the United States Food & Drug Administration (USFDA) to expand its neurology offerings in the US market. This innovative gabapentin formulation offers enhanced bioavailability, accurate dosing, and straightforward administration for patients, facilitating more consistent therapeutic outcomes, better symptom management, and increased convenience for long-term treatment. Gabapentin tablets USP, 600 mg, provide diverse therapeutic capabilities, enabling effective treatment of various neurological ailments such as neuropathic pain and partial seizures through reliable dosage and demonstrated clinical efficacy.

Who Are The Companies Participating In The Gabapentin Market Environment?

Major companies operating in the gabapentin market are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan Inc., Apotex Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Lupin Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited, Torrent Pharmaceuticals Ltd., Ipca Laboratories Private Limited, Granules India Limited, Medley Pharmaceuticals Limited, Wockhardt Limited, Epic Pharma LLC, Healing Pharma India Pvt. Ltd., Rochem International Inc., Accord Healthcare Limited, Strides Pharma Science Limited, Ascend Laboratories LLC

Get The Full Gabapentin Market Report:

https://www.thebusinessresearchcompany.com/report/gabapentin-global-market-report

Which Region Is The Top Contributor To The Gabapentin Market By Share?

North America was the largest region in the gabapentin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gabapentin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Gabapentin Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/gabapentin-global-market-report

Browse Through More Reports Similar to the Global Gabapentin Market 2026, By The Business Research Company

Glycomic Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/glycomic-therapeutics-global-market-report

Glycopeptide Antibiotics Market Report 2026

https://www.thebusinessresearchcompany.com/report/glycopeptide-antibiotics-global-market-report

Antiglaucoma Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/antiglaucoma-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795